title: The impact of recent data on our understanding of the roles of COX-1 and COX-2 in gastrointestinal pathophysiology.
abstract: Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most commonly prescribed drugs in the world. In general, these agents have comparable efficacy and are well tolerated, although their use may be limited by their gastrointestinal (GI) tolerability. After the discovery of cyclo-oxygenase (COX)-1 and COX-2 isoforms, COX-1 was postulated to play a role in gastroprotection and COX-2 a role in inflammation and, as known, selective COX-2 inhibitors were developed in an attempt to reduce gastrointestinal toxicity while maintaining therapeutic efficacy. However, recent research challenges the common thinking beyond COX inhibition and related GI adverse reactions showing that GI tolerability might be the result of a combination of COX-dependent mechanisms and the so-called topical effects which NSAIDs - especially those with acid pK - may exert on the GI mucosa. GI tolerability is even more important in the rheumatology patient with concomitant co-morbidities, such as inflammatory bowel disease (IBD), for which the use of NSAIDs is controversial. Results from clinical studies in these patient groups show that NSAIDs such as nimesulide, with its preferential inhibitory activity on the COX-2 isoform and the lack of a topical effect, do not influence the evolution of IBD in patients requiring NSAID treatment for concomitant arthritic complaints. These results further reinforce the GI safety profile of nimesulide in comparison with other NSAIDs, even in particular circumstances, for example in patients with IBD in whom treatment with a NSAID is indicated.
authors: Department of Medicine, Guy's, King's, St Thomas' School of Medicine, University of London, Bessemer Road, London, SE5 9PJ, UK. ingvar.bjarnason@kcl.ac.uk
authors: Ingvar
authors: I
authors: Bjarnason
mesh_terms: D051545:Cyclooxygenase 1 / Q000378:metabolism*; D051546:Cyclooxygenase 2 / Q000378:metabolism*; D041981:Gastrointestinal Tract / Q000201:enzymology*; D006801:Humans; D013449:Sulfonamides / Q000008:administration & dosage
chemical_list: D013449:Sulfonamides; D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2; C012655:nimesulide
references: Biochem Pharmacol. 2001 Mar 15;61(6):631-7
references: 11266647
references: Inflamm Bowel Dis. 2004 Jul;10(4):352-6
references: 15475742
references: Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7563-8
references: 10377455
references: Trends Pharmacol Sci. 1999 Jan;20(1):4-6
references: 10101953
references: Inflamm Bowel Dis. 2004 Nov;10(6):751-7
references: 15626893
references: Drug Saf. 2001;24(14):1081-90
references: 11735663
references: Aliment Pharmacol Ther. 2003 Jun 1;17(11):1371-80
references: 12786631
references: Agents Actions Suppl. 1995;46:41-50
references: 7610990
references: Dig Dis Sci. 2006 Jan;51(1):168-72
references: 16416231
references: Aliment Pharmacol Ther. 2004 Jul;20 Suppl 2:48-58
references: 15335413
references: N Engl J Med. 2005 Mar 17;352(11):1092-102
references: 15713943
references: Am J Med. 1998 Jul 27;105(1B):31S-38S
references: 9715832
references: Gastroenterology. 2003 Aug;125(2):637-8
references: 12891585
references: Arzneimittelforschung. 1995 Oct;45(10):1093-5
references: 8595066
references: Aliment Pharmacol Ther. 2004 Nov 15;20(10):1035-43
references: 15569105
references: Drugs. 1990;40 Suppl 5:1-11
references: 2081486
references: World J Gastroenterol. 2006 Mar 14;12(10):1509-10
references: 16570341
references: Eur J Clin Pharmacol. 1998 Jul;54(5):393-7
references: 9754982
references: Gastroenterology. 1993 Jun;104(6):1832-47
references: 8500743
references: Gastroenterology. 2000 Sep;119(3):706-14
references: 10982765
references: Gut. 2001 Mar;48(3):339-46
references: 11171823
references: BMJ. 2006 Jun 3;332(7553):1302-8
references: 16740558
references: N Engl J Med. 2005 Mar 17;352(11):1081-91
references: 15713945
references: Proc Natl Acad Sci U S A. 1992 Jun 1;89(11):4888-92
references: 1594589
references: Joint Bone Spine. 2005 Jul;72(4):286-94
references: 16038840
references: J Clin Invest. 2006 Jan;116(1):4-15
references: 16395396
references: Drug Saf. 2004;27(6):411-20
references: 15144234
references: Am J Gastroenterol. 2000 Aug;95(8):1859-61
references: 10950025
references: Best Pract Res Clin Gastroenterol. 2001 Oct;15(5):723-38
references: 11566037
references: Am J Gastroenterol. 2002 Apr;97(4):910-4
references: 12008668
references: Clin Gastroenterol Hepatol. 2006 Feb;4(2):196-202
references: 16469680
references: Gastroenterology. 2002 Jun;122(7):1913-23
references: 12055598